Tenapanor 2HCl (formerly AZD-1722; AZD1722; RDX-5791; RDX 5791; Ibsrela), the dihydrochloride salt of Tenapanor, is a novel and potent inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3 approved in 2019 for the treatment of irritable bowel syndrome with constipation (IBS-C).

BI-9627 is a novel and highly potent NHE1 (sodium-hydrogen exchanger isoform 1) inhibitor with with an EC50 of 31 nM.

Tenapanor (formerly RDX-5791; RDX 5791; AZD-1722; AZD1722; trade name Ibsrela) is a first-in-class inhibitor of sodium-hydrogen exchanger (NHE3) approved by FDA in 2019 for the treatment of irritable bowel syndrome with constipation (IBS-C).